Mecanismos de acción de la inmunoglobulina humana en las enfermedades dermatológicas pediátricas

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.
    Science 11/1998; 282(5388):490-3. DOI:10.1126/science.282.5388.490 · 31.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies identified autoantibodies against the IgE high affinity receptor alpha-chain, Fc epsilon RI alpha, in sera of selected patients with severe chronic idiopathic urticaria. We have now determined the incidence of anti-Fc epsilon RI alpha autoantibodies in a group of 163 patients. Intradermal injection of autologous serum caused skin reactions indicative of mast cell degranulation in 98 (60%) patients. Based on histamine release from IgE-sensitized and nonsensitized basophil leukocytes of healthy donors, we detected anti-Fc epsilon RI alpha autoantibodies in sera from 38 (23%) urticaria patients and evidence for anti-IgE antibodies in a further nine patients. The sera that released histamine from basophils induced histamine release (4-34%, n = 12) from mast cells in incubated skin slices. Protein-G affinity chromatography of sera demonstrated that mast cell histamine release was IgG-mediated. Preincubation of sera or the IgG fraction with a recombinant alpha-chain of Fc epsilon RI inhibited histamine release from mast cells and basophils. Further studies with the mouse anti-human Fc epsilon RI alpha antibody 29C6 showed that mast cells and basophils were similarly sensitive to IgG-mediated direct cross-linking of Fc epsilon RI, with 0.01-1.0 micrograms/ml 29C6 evoking histamine release in each case. These studies demonstrate that circulating levels of anti-Fc epsilon RI alpha autoantibodies mediate histamine release from skin mast cells in vitro and, taken together with in vivo evidence of mast cell degranulation following intradermal injection of autologous serum, support the concept that anti-Fc epsilon RI alpha autoantibodies are relevant to the pathogenesis of severe chronic urticaria in about 25% of patients.
    Journal of Investigative Dermatology 06/1996; 106(5):1001-6. DOI:10.1111/1523-1747.ep12338544 · 6.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Caso clínico Revista Alergia México 2005;52(1):39-41 RESUMEN Se reporta el caso de una paciente joven, con pénfigo vulgar, de afectación mucocutánea, recalcitrante, con múltiples complicaciones, secundarias al uso crónico de corticoesteroides, y mielosupresión por azatioprina. Se le trató con dosis altas de inmunoglobulina humana intravenosa durante cinco días consecutivos y en tres semanas se logró la remisión total de las lesiones ampollosas. Por lo tanto, la inmunoglobulina intravenosa se considera una buena alternativa para el manejo del pénfigo vulgar, cuando no exista respuesta al trata-miento o se hayan manifestado complicaciones como consecuencia del uso prolongado de altas dosis de corticoesteroides. Palabras clave: pénfigo vulgar, inmunoglobulina intravenosa. ABSTRACT A case of a young woman with recalcitrant pemphigus vulgaris involving skin and mucosae, with multiple side effects due to the chronic use of corticosteroids and azathioprine related myelosuppression is presented. She received high doses of intravenous immunoglobulin for five consecutive days and showed a rapid disease control, with healing in three weeks. Remission observed in this patient supports the idea that intravenous immunoglobulin is a good alternative of treatment for patients with pemphigus vulgaris, when there is no response to it or when significant adverse effects appear as a result of its prolonged use.


Available from